December 8th 2009
£595 / $1040 / €745
As the impact of the recession bites who will survive or thrive? This highly-detailed 400+ page report evaluates the response and activity of 50 leading companies.
The orthopaedic market is one of the major medical device sectors with a track record of consistently providing good levels of return to developers and investors, and offering real benefits for healthcare professionals. However, the economic recession has hit health spending hard and companies have been forced to dig deep and fundamentally review their operations.
R&D – a victim of the recession
The new operating reality has seen companies cut costs, and spending on research and development has been drastically reduced. The focus has been on improving existing products and making them more competitive and affordable in the marketplace. With growing economic confidence this trend is set to be transformed.
Who will survive and who will thrive?
2010 is going to be a big year for a number of companies as all avenues for cutting costs are exhausted and cash reserves diminish to critical levels. These economic threats also represent opportunities to those companies that have the business acumen to prosper in the future.
The ability to readily assess the companies involved, research areas of topical interest, the products being developed, strategic collaborations and performance/funding is key to understanding this market. In over 400 information-packed pages, the expanded new edition of The Orthopaedic Company Review (published December 2009) evaluates 50 companies from multinationals to specialist organisations. All major orthopaedic, prosthetic and fixation devices are covered.
The following information is provided for each company...